Calls for papers
-
Drug delivery specialist Zeteo Biomedical has announced the availability of its first device for delivery to the lung, the AriesMR DPI, which the company describes as “a reloadable active dry powder inhaler designed for controlled… Read more . . .
-
Agomab Therapeutics has announced that the final part of a Phase 1 study of its AGMB-447 inhaled ALK5 inhibitor, which enrolled patients with idiopathic pulmonary fibrosis, demonstrated “a generally favorable safety and tolerability profile” in… Read more . . .
-
The Cystic Fibrosis Foundation has agreed to invest up to $7.3 million in Ride Therapeutics to support identification of potential delivery vehicles for inhaled genetic therapies for CF. According to the CFF, Ride plans to test millions… Read more . . .
-
According to Nasus Pharma, the FDA has cleared an IND for a study of Nasus’s NS002 intranasal dry powder epinephrine for the treatment of anaphylaxis. Nasus says that it also plans to initiate a pivotal… Read more . . .
-
Aptar Pharma will provide nasal delivery technology for a project led by Massachusetts General Hospital Assistant Professor Alice Stanton to develop a platform designed to improve development of therapies intended for nose-to-brain delivery. The company… Read more . . .
-
According to Hikma Pharmaceuticals, regulators in the US, Europe, and the UK have accepted submissions for the company’s epinephrine nasal spray for the treatment of anaphylaxis, and the company has also filed a submission in… Read more . . .
-
Inhaled mRNA developer Ethris has signed an agreement with the European Investment Bank (EIB), and the European Commission’s Health Emergency Preparedness and Response Authority (DG HERA) for a €30 million financing to support clinical development… Read more . . .
-
Pulmovant has announced that the Phase 2 PHocus clinical trial of its inhaled dry powder mosliciguat in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD) met its primary endpoint, demonstrating a significant reduction in… Read more . . .
-
Glenmark Pharmaceuticals has announced that Ryaltris olopatadine / mometasone nasal spray was approved by ANVISA earlier this year for the treatment of allergic rhinitis in patients aged 12 and over and that the company has… Read more . . .
-
OINDP instrument and testing specialist Proveris Scientific, which was acquired by Investindustrial earlier this year, has announced that experienced life sciences executive Daniel Tereau is the company’s new President and Chief Executive Officer 2026. Tereau was most… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA